Use of linezolid in children: an overview of recent advances

References

• Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother.46, 347–350 (2000).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Jones RN. Oxazolodinone antibiotics. Lancet358, 1975–1982 (2001).
   PubMed Web of Science ®Google Scholar
• Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J. Antimicrob. Chemother.50, 1017–1026 (2002).
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug resistant, Gram positive infections: experience from a compassionate-use program. Clin. Infect. Dis.36, 159–168 (2003).
   PubMed Web of Science ®Google Scholar
• El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl. Infect. Dis.5, 121–125 (2003).
   PubMedGoogle Scholar
• Marcinak JF, Frank AL. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children. Expert Rev. Anti Infect. Ther.4(1), 91–100 (2006).
   PubMedGoogle Scholar
• Lin AH, Murray RW, Vidmar TJ et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother.41, 2127–2131 (1997).
   PubMed Web of Science ®Google Scholar
• Al-Tatari H, Abdel-Haq N, Chearskull P. Antibiotics for treatment of resistant Gram-positive coccal infections. Indian J. Pediatr.73(4), 323–334 (2006).
   PubMedGoogle Scholar
• Goldstein EJ, Citron DM, Warren YA. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother.50(8), 2875–2879 (2006).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG and the Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis.32, 402–412 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis.34, 1481–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents Chemother.45(3), 764–767 (2001).
   PubMed Web of Science ®Google Scholar
• Moylett EH, Pacheco SE, Brown-Elliott BA et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin. Infect. Dis.36(3), 313–318 (2003).
   PubMed Web of Science ®Google Scholar
• Vayalumkal JV, Jadavji T. Children hospitalized with skin and soft tissue infections: a guide to antibacterial selection and treatment. Paediatr. Drugs8(2), 99–111 (2006).
   PubMedGoogle Scholar
• Roberts SM, Freeman AF, Harrington SM et al. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr. Infect. Dis. J.25(6), 562–564 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Deville JG, Yogev R et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J.22(8), 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Succesful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin. Infect. Dis.32, 1373–1375 (2001).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Afghani B, Lopez P et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J.22(Suppl. 9), S178–S185 (2003).
   PubMed Web of Science ®Google Scholar
• Tan TQ. Update on the use of linezolid: a pediatric perspective. Pediatr. Infect. Dis. J.23(10), 955–956 (2004).
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother.45(6), 1843–1846 (2001).
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother.51, 17–25 (2003).
   Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C] linezolid to healthy human subjects. Drug Metab. Dispos.29, 1136–1145 (2001).
   PubMed Web of Science ®Google Scholar
• Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab. Dispos.28, 1014–1017 (2000).
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR et al. Pharmacokinetics of linezolid in subjects with various degrees of renal function and on dialysis. Presented at: American Society for Microbiology, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, (1999) (Abstract A-54).
   Google Scholar
• Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr. Infect. Dis. J.22(Suppl. 9), S153–S157 (2003).
   PubMed Web of Science ®Google Scholar
• Kearns GL, Jungbluth GL, Abdel-Rahman SM et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin. Pharmacol. Ther.74(5), 413–422 (2003).
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Goa KL. Linezolid: in infants and children with severe Gram-positive infections. Paediatr. Drugs5(6), 419–429 (2003).
   PubMedGoogle Scholar
• Kearns GL, Abdel-Rahman SM, Blumer JL et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr. Infect. Dis. J.19, 1178–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Kaplan SL. Use of linezolid in children. Introduction. Pediatr. Infect. Dis. J.22(Suppl. 9), S151–S152 (2003).
   PubMedGoogle Scholar
• Ladhani S, Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. Paediatr. Drugs7(2), 77–102 (2005).
   PubMedGoogle Scholar
• Kaplan SL, Patterson L, Edwards KM et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr. Infect. Dis. J.20, 488–494 (2001).
   PubMed Web of Science ®Google Scholar
• Yogev R, Patterson LE, Kaplan SL et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr. Infect. Dis. J.22(Suppl. 9), S172–S177 (2003).
   PubMed Web of Science ®Google Scholar
• Butler KM. Enterococcal infection in children. Semin. Pediatr. Infect. Dis.17(3), 128–139 (2006).
   PubMedGoogle Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet.42(13), 1129–1140 (2003).
   PubMed Web of Science ®Google Scholar
• Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin. Infect. Dis.38(8), 1058–1064 (2004).
   PubMed Web of Science ®Google Scholar
• Fagon J, Patrick H, Haas DW et al. Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin; Nosocomial Pneumonia Group. Am. J. Respir. Crit. Care Med.161, 753–762 (2000).
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest124(5), 1789–1797 (2003).
   PubMed Web of Science ®Google Scholar
• Wible K, Trefnghi M, Bruss J et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr. Infect. Dis. J.22, 315–323 (2003).
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother.51(Suppl. 2), 45–53 (2003).
   PubMed Web of Science ®Google Scholar
• Saiman L, Golffarb J, Kaplan SL et al. Safety and tolerability of linezolid in children. Pediatr. Infect. Dis. J.22, 193–200 (2003).
   PubMed Web of Science ®Google Scholar
• Meissner HC, Townsend T, Wenman W et al. Hematologic effects of linezolid in young children. Pediatr. Infect. Dis. J.22(Suppl. 9), S186–S192 (2003).
   PubMedGoogle Scholar
• Bressler AM, Zimmer SM, Gilmore JL et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis.4, 528–531 (2004).
   PubMed Web of Science ®Google Scholar
• Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S. Linezolid-associated serotonin syndrome: what we can learn from cases reported so far. J. Antimicrob. Chemother.56(6), 1176–1178 (2005).
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis.42(8), 1111–1117 (2006).
   PubMed Web of Science ®Google Scholar
• Steele RW, Russo TM, Thomas MP. Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children. Clin. Pediatr.45, 245–250 (2006).
   PubMedGoogle Scholar
• Bishop E, Melvani S, Howden BP et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother.50, 1599–1602 (2006).
   PubMed Web of Science ®Google Scholar
• Vigano SM, Edefonti A, Ferraresso M et al. Succesful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient. Pediatr. Nephrol.20, 1186–1188 (2005).
   PubMedGoogle Scholar